FDA In 'Very Early Stages' of Looking at Centralized Document Review
The FDA is in the beginning stages of looking at a centralized review model for import entry, said a FDA spokeswoman. "FDA is currently exploring the idea of using a 'centralized' review model for import entry review," she said. "This…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
exploration is in the very early stages and will be looking at whether the model is feasible, whether any efficiencies could be expected from such a model, if there would be any benefits to FDA and/or the regulated industry from such a model." An FDA official recently discussed the issue at the National Customs Brokers and Forwarders Association of America conference. (See ITT's Online Archives 12091423 for summary of the FDA official's remarks.)